Outlook Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q1 2015 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Outlook Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2015 to Q2 2024.
  • Outlook Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$19.6M, a 7.83% decline year-over-year.
  • Outlook Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$61.3M, a 12.1% decline year-over-year.
  • Outlook Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$53.1M, a 15.8% increase from 2022.
  • Outlook Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$63.1M, a 21.9% decline from 2021.
  • Outlook Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$51.7M, a 40.4% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$61.3M -$19.6M -$1.42M -7.83% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 -$59.9M -$18.9M -$12.1M -177% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 -$47.8M -$10.3M +$5.36M +34.2% Oct 1, 2023 Dec 31, 2023 10-Q 2024-02-14
Q3 2023 -$53.1M -$12.5M +$1.53M +10.9% Jul 1, 2023 Sep 30, 2023 10-K 2023-12-22
Q2 2023 -$54.7M -$18.1M -$1.12M -6.56% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$53.5M -$6.84M +$12.1M +63.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 -$65.6M -$15.7M -$2.54M -19.3% Oct 1, 2022 Dec 31, 2022 10-Q 2024-02-14
Q3 2022 -$63.1M -$14M -$552K -4.11% Jul 1, 2022 Sep 30, 2022 10-K 2023-12-22
Q2 2022 -$62.5M -$17M -$5.55M -48.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 -$57M -$18.9M -$6.28M -49.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$50.7M -$13.1M +$1.04M +7.34% Oct 1, 2021 Dec 31, 2021 10-Q 2023-02-14
Q3 2021 -$51.7M -$13.4M -$3.42M -34.2% Jul 1, 2021 Sep 30, 2021 10-K 2022-12-29
Q2 2021 -$48.3M -$11.5M +$404K +3.4% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-10
Q1 2021 -$48.7M -$12.6M -$5.86M -86.7% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-13
Q4 2020 -$42.8M -$14.2M -$6.01M -73.4% Oct 1, 2020 Dec 31, 2020 10-Q 2022-02-14
Q3 2020 -$36.8M -$10M +$2.68M +21.1% Jul 1, 2020 Sep 30, 2020 10-K 2021-12-23
Q2 2020 -$39.5M -$11.9M -$6.24M -110% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-13
Q1 2020 -$33.3M -$6.76M +$942K +12.2% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-14
Q4 2019 -$34.2M -$8.18M +$2.07M +20.2% Oct 1, 2019 Dec 31, 2019 10-Q 2021-02-16
Q3 2019 -$36.3M -$12.7M -$278K -2.24% Jul 1, 2019 Sep 30, 2019 10-K 2020-12-23
Q2 2019 -$36M -$5.64M +$1.58M +21.8% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-14
Q1 2019 -$37.6M -$7.71M -$875K -12.8% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-15
Q4 2018 -$36.7M -$10.3M -$7.08M -223% Oct 1, 2018 Dec 31, 2018 10-Q 2020-02-14
Q3 2018 -$29.6M -$12.4M -$9.5M -326% Jul 1, 2018 Sep 30, 2018 10-K 2019-12-19
Q2 2018 -$20.1M -$7.22M +$117K +1.59% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-14
Q1 2018 -$20.3M -$6.83M +$1.01M +12.8% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-15
Q4 2017 -$21.3M -$3.18M +$14.6M +82.1% Oct 1, 2017 Dec 31, 2017 10-Q 2019-02-14
Q3 2017 -$35.9M -$2.91M +$7.04M +70.8% Jul 1, 2017 Sep 30, 2017 10-K 2018-12-18
Q2 2017 -$42.9M -$7.34M +$14.7M +66.7% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-14
Q1 2017 -$57.6M -$7.84M -$4.88M -165% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-15
Q4 2016 -$52.7M -$17.8M -$1.38M -8.42% Oct 1, 2016 Dec 31, 2016 10-Q 2018-02-14
Q3 2016 -$51.3M -$9.95M Jul 1, 2016 Sep 30, 2016 10-K 2017-12-29
Q2 2016 -$22M -$11M -99.4% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-14
Q1 2016 -$2.95M +$11M +78.9% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-15
Q4 2015 -$16.4M Oct 1, 2015 Dec 31, 2015 10-Q 2017-02-14
Q2 2015 -$11M Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-15
Q1 2015 -$14M Jan 1, 2015 Mar 31, 2015 10-Q 2016-06-27
* An asterisk sign (*) next to the value indicates that the value is likely invalid.